Puma Biotechnology Files 8-K for Routine Delaware Law Bylaw Update

Rhea-AI Filing Summary

Puma Biotechnology, Inc. (Nasdaq: PBYI) filed a Form 8-K announcing that its Board of Directors approved and adopted Fifth Amended and Restated Bylaws on June 19, 2025. The revisions align the company’s corporate governance documents with recent updates to Delaware corporate law and include conforming and ministerial edits. No changes to the company’s fiscal year, capital structure, or financial guidance were disclosed. The amended bylaws are filed as Exhibit 3.1 and incorporated by reference.

Insights

Corporate Governance Expert

TL;DR: Routine bylaw update; aligns with Delaware law, minimal direct investor impact.

The amendment reflects typical housekeeping to ensure compliance with the latest Delaware General Corporation Law changes. Such updates generally refine procedural matters—e.g., notice periods, virtual meetings, or officer titles—without altering shareholder rights materially. No anti-takeover provisions or capital structure revisions were noted, so the filing is largely administrative. Investors should monitor future proxy materials to see if any substantive governance changes emerge, but for now the impact on valuation or control dynamics is negligible.

Financial Analyst

TL;DR: Neutral filing; no financial or strategic implications for PBYI’s outlook.

The 8-K contains no operational, revenue, or expense information and therefore does not affect earnings estimates or cash-flow projections. Because the changes are procedural, the company’s risk profile, credit outlook, and capital allocation priorities remain unchanged. The filing should not move the stock absent additional context.

8-K Event Classification

2 items: 5.03, 9.01

2 items

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance

The company amended its charter documents, bylaws, or changed its fiscal year.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001401667 0001401667 2025-06-19 2025-06-19

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 19, 2025

PUMA BIOTECHNOLOGY, INC.

(Exact Name of Registrant as Specified in its Charter)

--12-31

Delaware	001-35703	77-0683487
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

10880 Wilshire Boulevard, Suite 2150

Los Angeles, California 90024

(Address of principal executive offices) (Zip Code)

(424) 248-6500

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		PBYI		The Nasdaq Stock Market LLC (Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On June 19, 2025, the Board of Directors of Puma Biotechnology, Inc. (the “Company”) approved and adopted an amendment and restatement of the Company’s Fourth Amended and Restated Bylaws (as so amended, the “Amended Bylaws”) primarily to revise provisions in order to be more in line with certain updates to Delaware law. The Amended Bylaws also incorporate various conforming, ministerial and other related changes.

A copy of the Amended Bylaws is filed as Exhibit 3.1 to this current report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
3.1 104.1		Fifth Amended and Restated Bylaws of Puma Biotechnology, Inc. Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PUMA BIOTECHNOLOGY, INC.
Date: June 24, 2025	By:	/s/ Alan H. Auerbach
		Alan H. Auerbach
		Chief Executive Officer and President

FAQ

Why did Puma Biotechnology (PBYI) file a Form 8-K on June 19, 2025?

The company disclosed that its Board adopted Fifth Amended and Restated Bylaws to align with recent Delaware law updates.

Does the amended bylaw filing affect PBYI’s financial guidance or earnings?

No. The 8-K contains no financial data or guidance changes.

Were any anti-takeover provisions added to Puma Biotechnology’s bylaws?

The filing mentions only compliance and ministerial updates; no new anti-takeover measures were disclosed.

Where can investors find the full text of the new bylaws?

The complete bylaws are attached as Exhibit 3.1 to the Form 8-K and available on the SEC’s EDGAR system.

Did Puma Biotechnology announce any leadership changes in this 8-K?

No leadership or management changes were reported; the CEO’s signature is procedural.